Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
1. A composition comprising:
(i) a plurality of killed intact bacterial cells, each killed intact bacterial cell of said plurality comprising a functional nucleic acid,
(ii) a bispecific ligand comprised of a first arm that carries specificity for a surface structure of a bacterial cell of (i) and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein said mammalian cell surface receptor activates reeeptor-mediated endocytosis of said killed bacterial cell, and
(iii) a pharmaceutically acceptable carrier therefor.
2. The composition according to claim 1 , wherein said functional nucleic acid is a regulatory RNA.
3. The composition according to claim 1 , wherein said composition is essentially free of endotoxin.
4. The composition according to claim 1 , wherein said functional nucleic acid targets the transcript of a protein that contributes to drug resistance.
5. The composition according to claim 4 , wherein said functional nucleic acid is an siRNA, shRNA or miRNA that targets the transcript of a protein that contributes to drug resistance.
6. The composition according to claim 4 , wherein said functional nucleic acid is an antisense molecule that targets the transcript of a protein that contributes to drug resistance.
7. The composition according to claim 4 , wherein said functional nucleic acid is a ribozyme that targets the transcript of a protein that contributes to drug resistance.
8. The composition according to claim 4 , wherein said functional nucleic acid targets the transcript of P-glycoprotein or MDR-3.
9. The composition of claim 4 , further comprising a drug.
10. The composition of claim 9 , wherein said functional nucleic acid targets the transcript of a protein that contributes to resistance to said drug.
11. The composition of claim 10 , wherein said drug is packaged in a killed bacterial cell.
12. The composition of claim 10 , wherein said functional nucleic acid and said drug are packaged within the same killed bacterial cell.
13. The composition of claim 1 , wherein said bispecific ligand comprises an antibody or antibody fragment.
14. The composition of claim 1 , wherein said bispecific ligand comprises polypeptide or carbohydrate.
15. The composition according to claim 1 , wherein said bacterial cell surface structure is an O-polysaccharide component of a lipopolysaccharide on said killed bacterial cell surface.
16. The composition of claim 1 , wherein said first arm and said second arm are monospecific.
17. The composition of claim 1 , wherein said first arm and said second arm are multivalent.
18. A composition consisting essentially of intact killed bacterial cells that contain a functional nucleic acid, wherein the functional nucleic acid is plasmid-free and there is an absence from the killed bacterial cells of a construct for in situ expression of the functional nucleic acid.
19. A composition comprising:
(i) a plurality of intact killed bacterial cells, each killed bacterial cell of said plurality encompassing a functional nucleic acid that targets transcription of P-glycoprotein,
(ii) a bispecific ligand comprised of a first arm that carries specificity for a surface structure of a bacterial cell of (i) and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein said mammalian cell surface receptor activates receptor-mediated endocytosis of said killed bacterial cell, and
(iii) a pharmaceutically acceptable carrier therefor.